SCHEMBL4469264

SCHEMBL4469264

Cc1cc(Cl)ccc1-c1cnc(I)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.41
GRM5 P41594 1/20 0.37
IDO1 P14902 1/20 0.37
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPK10 P53779 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
HSP90AB1 P08238 2/20 0.35
HSD11B1 P28845 1/20 0.34
NPBWR1 P48145 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
ABL1 P00519 1/20 0.33
CASP3 P42574 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469279 0.83 HSP90AA1 (0.44) IDO1MEN1ALDH1A1MAPTKMT2A
SCHEMBL4477259 0.80 ALOX5AP (0.49) NOTUMALOX5APFEN1
SCHEMBL4475272 0.76 NOTUM (0.38) NOTUMGRM5IDO1CYP3A4CYP1A2
SCHEMBL5406690 0.75 NOTUM (0.41) NOTUMGRM5IDO1CYP3A4HSD11B1
SCHEMBL4488940 0.73 NOTUM (0.38) NOTUMGRM5IDO1CYP3A4CYP1A2
SCHEMBL29719717 0.71 NOTUM (0.53) NOTUMIDO1CYP3A4HSD11B1CASP3
SCHEMBL255658 0.71 NPC1 (0.47) NOTUMMEN1ALDH1A1MAPTMAPK10
SCHEMBL4337894 0.69 NPC1 (0.50) NOTUMGRM5CYP1A2ALDH1A1MAPT
SCHEMBL446276 0.68 PIK3CA (0.43) NOTUMGRM5MEN1MAPTKMT2A
SCHEMBL27581704 0.68 JAK2 (0.47) NOTUMGRM5MAPTMAPK10KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 NOTUM 2244/4885GRM5 119/4885IDO1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.